This is a working overview of 强制降解, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-15 and is reviewed periodically as new material appears.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Google Cloud Platform (GCP) - Storage, Pub/Sub, FireStore Central Configuration Server (CCS) SSO CF Admin Integration (SAML/LDAP) including CF Admin API updates JSON Web Tokens Avro & Protocol Buffer Serialization New PDF Engine Library Updates (Java, Solr, Hibernate) Native GraphQL Query support Bug fixes
A Broadway production named Shining City was Platt's Broadway debut in 2006. The play was set in Dublin, and Platt's role was the tortured protagonist, John. Shining City's director said, "There is one word to describe Oliver. It's 'humanity.' He's got that everyman quality. He's a contradictory human being with flaws and strengths. And he's loveable. He can simultaneously make you laugh and break your heart. Oliver has brought to the role of John what I expected and more: tremendous inventiveness and sensitivity." Platt visited Dublin to prepare for the role and ensure his performance was authentic. He was nominated for a Tony Award for "Best Performance by a Leading Actor in a Play". In 2007, Platt played the part of Yankees owner George Steinbrenner in the ESPN mini-series The Bronx Is Burning. Platt signed onto the project after John Turturro was confirmed as Billy Martin, because "This thing lives or dies by that portrayal ... I think it's great casting. God knows he has the intensity." Platt starred in the pilot episode of The Thick of It, a remake of the British show of the same name in 2007. The series was not picked up by ABC. Platt starred as Nathan Detroit, alongside Lauren Graham as Miss Adelaide, in the Broadway revival of Guys and Dolls which began performances at the Nederlander Theatre on February 3, 2009, and officially opened on March 1, 2009. The production closed on June 14, 2009, after 113 performances. Platt starred as White House Chief of Staff Carl Anheuser in Roland Emmerich's 2012, a disaster film released November 13, 2009.
=== R139w === One further single nucleotide polymorphism, found homozygous in 0% to 5% of different ethnic population, is leading to an amino acid exchange on position 139 from arginine to tryptophane. Furthermore, an alternative RNA splicing site is created leading to a loss of the quinone binding site. The variant protein of NQO1*3 has similar stability as its wild-type counterpart. The variation between the two is substrate specific and it has reduced activity for some substrates. It has been recently shown that the NQO1*3 polymorphism may also lead to reduced NQO1 protein expression.
Half-Life: Blue Shift is an expansion pack for the first-person shooter video game Half-Life (1998). It was developed by Gearbox Software and published by Sierra On-Line. Blue Shift was the second expansion for Half-Life, originally intended as part of a Dreamcast port of Half-Life. Although the Dreamcast port was cancelled, the Windows version was released as a standalone product on June 12, 2001. As with Gearbox's previous expansion pack, Opposing Force (1999), Blue Shift returns to the setting and events of Half-Life, but portrays the story through the eyes of another character. Players control security guard Barney Calhoun, employed by the Black Mesa Research Facility, who must fight his way to safety during an alien invasion. Blue Shift also includes a graphics pack that upgrades the Half-Life models and textures. Blue Shift received mixed reviews. Many reviewers were critical of the short length and lack of new content, although the new graphics were praised.
Sources: en.wikipedia.org
He found that the proportion of uranium X to uranium Z extracted from several kilograms of uranyl nitrate remained constant over time, strongly indicating that uranium X was the mother of uranium Z. To prove this, Hahn obtained a hundred kilograms of uranyl nitrate; separating the uranium X from it took weeks. He found that the half-life of the parent of uranium Z differed from the known 24-day half-life of uranium X1 by no more than two or three days, but was unable to get a more accurate value. Hahn concluded that uranium Z and uranium X2 were both the same isotope of protactinium (protactinium-234), and they both decayed into uranium II (uranium-234), but with different half-lives. Uranium Z was the first example of nuclear isomerism. Walther Gerlach later remarked that this was "a discovery that was not understood at the time but later became highly significant for nuclear physics". Not until 1936 was Carl Friedrich von Weizsäcker able to provide a theoretical explanation of the phenomenon. For this discovery, whose full significance was recognised by very few, Hahn was again proposed for the Nobel Prize in Chemistry by Bernhard Naunyn, Goldschmidt and Planck.
=== Failed proposed changes === 2015: Proposals to amalgamate local councils in Wellington and Northland were accepted by the Local Government Commission for consideration, although following consultation they ultimately were not formed into a final proposal. The status quo remains. 2015: Amalgamation of four local councils and the regional council in Hawke's Bay was proposed by the Local Government Commission. A district wide referendum was held in Sep-2015, and the proposal was defeated by 66% of voters. 2015: The Local Government Commission received a proposal to review local government arrangements on the West Coast. In August 2016 the Commission decided to progress the application. The Commission then invited alternative applications to the original application. The Commission's call for alternative reorganisation applications or other proposals for change to West Coast local government arrangements closed on 15 March 2017. The Commission received 23 responses, 19 of which made specific proposals for change. In December 2017 the Local Government Commission determined its preferred option for local government reorganisation on the West Coast to be the transfer of district plan preparation from the Buller, Grey and Westland district councils to the West Coast Regional Council. 2017: The Local Government Commission received a proposal to amalgamate the Masterton, Carterton and South Wairarapa District Councils into a combined Wairarapa District Council. The proposal was defeated by referendum with 59% of voters rejecting the proposed merger.
== Adverse events == The safety of benzhydrocodone/APAP was evaluated in a total of 200 healthy adults in six phase 1 studies. The subjects received at least one oral dose of benzhydrocodone/APAP. The most common adverse events in these studies were nausea (21.5%), somnolence (18.5%), vomiting (13.0%), constipation (12.0%), pruritus (11.5%), dizziness (7.5%) and headache (6.0%). Benzhydrocodone/APAP use with serotonergic drugs can cause serotonin syndrome. Mixed agonist/antagonist and partial agonist opioids may reduce the analgesic effect of benzhydrocodone/APAP or cause withdrawal symptoms. MAOIs can increase the effects of benzhydrocodone/APAP.
Americium-243, an alpha emitter, has a half-life of 7350 years, the longest of all americium isotopes. It is formed in the nuclear fuel cycle mainly by neutron capture on plutonium-242 followed by beta decay. Production increases exponentially with increasing burnup as a total of 5 neutron captures on 238U are required. If MOX-fuel is used, particularly MOX-fuel high in 241Pu and 242Pu, more americium overall and more 243Am will be produced. It decays by either emitting an alpha particle (decay energy 5.439 MeV) to become 239Np, which then quickly goes to 239Pu, or, very rarely, spontaneous fission. The fission rate is about 60% that of americium-241 or about 0.7/g/s. As for the other americium isotopes, and more generally for all alpha emitters, 243Am is carcinogenic in case of internal contamination after being inhaled or ingested. 243Am also presents a risk of external irradiation associated with the gamma ray emitted by its short-lived decay product 239Np. The external irradiation risk for the other two americium isotopes (241Am and 242mAm) is less than 10% of that for americium-243.
=== Eye morphology === The lens of the eye changes in curvature. Because of decreased androgen levels, the meibomian glands (the sebaceous glands on the upper and lower eyelids that open up at the edges) produce less oil. Because oil prevents the tear film from evaporating, this change may cause dry eyes.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.